--- title: 'Senior Medical Science Liaison - DMD/Neuromuscular (West Coast) at REGENXBIO' canonical: 'https://feeny.ai/job/senior-medical-science-liaison-dmd-neuromuscular-west-coast-regenxbio-west-coast-yerem2kwy7ca' type: 'job' last_seen: '2026-09-14' --- # Senior Medical Science Liaison - DMD/Neuromuscular (West Coast) at REGENXBIO - **Company:** REGENXBIO - **Location:** West Coast - **Employment:** full-time - **Work type:** remote - **Posted:** 2026-06-23 - **Last confirmed live:** 2026-09-14 - **Apply:** https://jobs.lever.co/regenxbio/623b4f0f-a570-4055-b39b-9e45101b8514 ## Job description ## Who we are REGENXBIO is an exceptional place to work. You'll have the opportunity to collaborate with some of the best and the brightest people, touch amazing science, and be a part of extraordinary plans. Our core values: Trust, Accountability, Perseverance, and Innovation drive everything we do. We aim to bring these values to life every day with all that we do, and we believe that what we do matters - to patients, to their families, and to their communities. The Opportunity: As a Senior Medical Science Liaison, you will provide support for REGENXBIO Rare Disease pre-commercial clinical trials and scientific collaborations with a focus on our Duchenne Muscular Dystrophy program. This is an exciting opportunity for an innovative MSL with an entrepreneurial spirit who enjoys building networks, interacting with KOLs, conducting scientific exchange, and supporting scientific conferences. What you'll be doing: - Support clinical trial recruitment and site outreach; communicate coordinated feedback to the Clinical Operations, Clinical Development, and Duchenne Core teams. - Serve as the field-based Medical Affairs representative to establish and cultivate scientific relationships with KOLs in the Duchenne community. - Develop a strong understanding of clinical practice as it relates to Duchenne. - Participate in refining KOL mapping; develop and execute on a customer-centric tactical engagement plan to support Medical Affairs strategies. - Gather and share scientific insights via scientific exchange to inform executable and innovative Medical Affairs strategies. - Serve as a resource for addressing unsolicited medical questions about REGENXBIO’s trials and investigational products. - Provide clinical expertise in the development, management, and maintenance of clinical and scientific communications, including educational materials, meeting presentations and FAQs. - Attend medical conferences as MA representative:  assist with congress strategy / planning, medical booth staffing, competitive intelligence / insights gathering, and generating meeting summaries. - Support Patient Advocacy conferences and outreach as requested. - As a field-based position, you must be able to travel 50-70% of the time. - It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships and using clear communication to meet shared objectives. What we're looking for: - Master’s degree (MPH or equivalent) required. Doctorate level (MD, PharmD, PhD) preferred. - Minimum of 3 years of rare disease clinical or therapeutic experience in neuromuscular diseases, and/ or gene therapy with primary emphasis on field based scientific exchange and/or clinical trial support. - Superior communication, relationship building and interpersonal skills. - Ability to assimilate new clinical data quickly. - Proactive problem-solving skills. - Project management and medical writing skills. - Flexibility, resilience, and creativity/ innovation in their work - Ability to organize and lead high level projects. - Ability to proactively predict issues and solve problems. - Ability to work collaboratively with cross-functional teams. Why should you apply? By joining REGENXBIO, you will have the opportunity to be a part of a growing company, with an incredible team, who is passionate about developing novel AAV gene therapies for patients in need. We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, retirement plan with employer match, stock options at all levels, summer hours and more! The estimated compensation range for this role is $170,000 to $230,000 annually. The actual salary offered to the final candidate depends on a number of factors such as relevant work experience, skills, education, and years of experience. In addition, professional development is important to us.  By joining our team, you’ll have the opportunity to be exposed to challenging projects and have access to development resources to help you grow personally and professionally. ## About REGENXBIO ## Company Overview - **One-liner**: REGENXBIO is a clinical-stage biotechnology company developing one-time gene therapies for rare and retinal diseases using its proprietary AAV vector platform. - **Entity Type**: Public (NASDAQ: RGNX) - **Headquarters**: Rockville, Maryland, United States - **Founded**: 2008 (founded as a company; operations began in 2009) - **Founders**: Not publicly listed as individual founders; the company was spun out from the gene therapy research of the University of Pennsylvania and licensed its NAV Technology Platform from the university. ## Core Business - **Primary industry**: Biotechnology – Gene Therapy (AAV-based) - **Target customers**: B2B (pharma partners like AbbVie, Nippon Shinyaku) and B2G (regulatory agencies, clinical trial sites); ultimate customers are patients with rare and retinal diseases (Duchenne muscular dystrophy, MPS I, MPS II, wet AMD, diabetic retinopathy). - **Mission or purpose statement**: “To improve lives through the curative potential of gene therapy.” [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Products & Services - **NAV® Technology Platform**: Proprietary AAV vector gene delivery platform (including AAV8 and AAV9) used for internal programs and licensed to partners (e.g., Novartis for ZOLGENSMA®). - **ABBV-RGX-314** (in collaboration with AbbVie): Investigational one-time gene therapy for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). In pivotal clinical trials. - **RGX-202** (Duchenne muscular dystrophy): Phase I/II/III AFFINITY DUCHENNE® trial; pivotal phase expected to support BLA submission in 2026 using accelerated approval pathway. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **RGX-121** (MPS II – Hunter syndrome): In partnership with Nippon Shinyaku; late-stage development. - **RGX-111** (MPS I – Hurler syndrome): In partnership with Nippon Shinyaku; clinical development. - **Manufacturing**: In-house cGMP production facility (REGENXBIO Manufacturing Innovation Center – RMIC) in Rockville, MD, operational since mid-2022. ## Market Standing - **Valuation/Market Cap**: $447.8 million (as of recent data). [linkedin.com](https://linkedin.com/company/regenx) - **Key Metric**: Annual Revenue $170.4 million (primarily from license and collaboration revenue). [linkedin.com](https://linkedin.com/company/regenx) - **Notable Investors/Partners**: - AbbVie (collaboration for ABBV-RGX-314) - Nippon Shinyaku (partnerships for RGX-121 and RGX-111) - Novartis (licensee for ZOLGENSMA® using NAV vectors) - **Growth Signals**: - Headcount: 296 employees (+1.3% YoY). [linkedin.com](https://linkedin.com/company/regenx) - BLA submission for RGX-202 targeted for 2026. - RMIC facility operational since 2022, enabling scalable clinical and commercial manufacturing. - Scholarly output: 160 works, 7,337 citations, field-weighted citation impact of 2.6 (highly influential). [linkedin.com](https://linkedin.com/company/regenx) ## Competitive Advantages - **Proprietary NAV Technology Platform**: Exclusive rights to a large portfolio of AAV vectors (including AAV8 and AAV9), the foundation for multiple approved and investigational gene therapies. [ir.regenxbio.com](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) - **End-to-end capabilities**: Integrated in-house R&D, preclinical development, clinical development, and cGMP manufacturing. - **Proven platform**: Thousands of patients have been treated with AAV vectors from the NAV platform (including via Novartis’ ZOLGENSMA®). - **Late-stage pipeline**: Multiple programs in pivotal or near-pivotal trials (RGX-202, ABBV-RGX-314) with clear regulatory pathways. ## Strategic Focus - **Near-term**: Advance RGX-202 toward BLA submission in 2026; continue pivotal trials for ABBV-RGX-314 in wet AMD and diabetic retinopathy. - **Long-term**: Expand pipeline in retinal, neuromuscular, and neurodegenerative diseases; leverage RMIC for commercial-scale manufacturing; deepen partnerships with AbbVie and Nippon Shinyaku. - **Platform expansion**: Ongoing research to expand NAV vector capabilities and develop new AAV-based therapies. ## Why Work Here - **Mission-driven culture**: “Patient-focused, driven by results, fosters collaboration.” Core values emphasize accountability, innovation, and serving patients with limited therapeutic options. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Impactful work**: Opportunity to work on one-time gene therapies that could fundamentally alter the course of devastating diseases. - **Growth & stability**: Public company with late-stage pipeline, strong partnerships, and a clear path to commercialization. - **Location & facilities**: Headquarters in Rockville, MD, with a state-of-the-art cGMP manufacturing facility (RMIC) on site. - **Work policy**: Not explicitly stated as remote/hybrid; positions appear to be on-site (based on job listings in Rockville and field-based Medical Science Liaison roles). - **Perks**: Comprehensive and competitive benefits for employees and families. [regenxbio.com](https://www.regenxbio.com/culture-careers/) - **Engineering & science culture**: High scholarly output and citation impact; emphasis on cross-functional collaboration between research, manufacturing, and clinical teams. - **Recruitment note**: REGENXBIO warns of fraudulent job offers; all applications go through their official Lever portal. [regenxbio.com](https://www.regenxbio.com/culture-careers/) ## Sources 1. [regenxbio.com – Culture & Careers](https://www.regenxbio.com/culture-careers/) 2. [linkedin.com – REGENXBIO company page](https://linkedin.com/company/regenx) 3. [ir.regenxbio.com – 10-K Filing (Business Overview)](https://ir.regenxbio.com/static-files/92731f97-50e3-4285-b793-d2cdc99611aa) 4. [ir.regenxbio.com – Investor Overview](https://ir.regenxbio.com/investor-overview) 5. [jobs.lever.co – REGENXBIO careers](https://jobs.lever.co/regenxbio) ## Other roles at REGENXBIO - [Associate Director, People Business Partner](https://feeny.ai/job/associate-director-people-business-partner-regenxbio-rockville-fmx3gbzx681y) — Rockville, MD - [Director, Commercial Data, Advanced Analytics & Forecasting](https://feeny.ai/job/director-commercial-data-advanced-analytics-forecasting-regenxbio-remote-88y6fvc5kv5j) - [Market Development Director - Southeast Region](https://feeny.ai/job/market-development-director-southeast-region-regenxbio-remote-b1hhp987p5v1) - [Associate Director, Rare Disease Product Marketing](https://feeny.ai/job/associate-director-rare-disease-product-marketing-regenxbio-rockville-r2p05phcvmx8) — Rockville, MD - [Associate Director, Data & Information Architecture](https://feeny.ai/job/associate-director-data-information-architecture-regenxbio-rockville-b0m5vrmrm33p) — Rockville, MD - [Senior Medical Science Liaison - DMD/Neuromuscular (South)](https://feeny.ai/job/senior-medical-science-liaison-dmd-neuromuscular-south-regenxbio-remote-4qggqdykm9ym) - [Senior Medical Science Liaison - DMD/Neuromuscular (Northeast)](https://feeny.ai/job/senior-medical-science-liaison-dmd-neuromuscular-northeast-regenxbio-remote-47qpcgnnyhpc) - [Senior Director, Global Program Development Lead - DMD/Neuromuscular](https://feeny.ai/job/senior-director-global-program-development-lead-dmd-neuromuscular-regenxbio-xbereeg0zrc8) — Rockville, MD - [Senior Director/Director, Medical Science Liaisons (Neuromuscular/DMD)](https://feeny.ai/job/senior-director-director-medical-science-liaisons-neuromuscular-dmd-regenxbio-aeca83gb75e2)